Boehringer Ingelheim announces Phase III data of flibanserin in pre-menopausal women with HSDD

Ridgefield, CT, November 16, 2009 - Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).

Read the whole article on Science Blog

More from Science Blog